| Prev Close | 0.68 |
| Day Low/High | 0.68 / 0.71 |
| 52 Wk Low/High | 0.61 / 4.90 |
| Avg Volume | 609.00K |
| Exchange | NASDAQ |
| Shares Outstanding | 37.27M |
| Market Cap | 25.34M |
| EPS | -1.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies
Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression
PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor activity
Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075's potential as safe and effective treatment for solid tumor and hematological malignancies
The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors
The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy
Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate
